Ilginatinib is under clinical development by NS Pharma and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According to GlobalData, Phase II drugs for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ilginatinib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ilginatinib is under development for the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis , severe pneumonia and acute respiratory distress syndrome caused due covid-19. The drug candidate is administered orally as a tablet. NS-018 is a small molecule which acts by targeting JAK2/Src.
NS Pharma overview
NS Pharma is a pharmaceutical company that develops drugs for muscular disorders. Its pipeline portfolio includes Phase II stage investigational candidates, NS-018 to treat hematologic malignancies such as myelofibrosis, NS-065 and NCNP-01 for the treatment of orphan diseases such as duchenne muscular dystrophy.
For a complete picture of Ilginatinib’s drug-specific PTSR and LoA scores, buy the report here.